Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: Results of prospectively designed overviews of randomised trials

Lancet

Volumn 356, Issue 9246, 2000, Pages 1955-1964

  Neal, B ^a   MacMahon, S ^a   Chapman, N ^a   Cutler, J ^a   Fagard, R ^a   Whelton, P ^a   Yusuf, S ^a   Agodoa, L ^a   Baigent, C ^a   Black, H ^a   Boissel, J P ^a   Brenner, B ^a   Brown, M ^a   Bulpitt, C ^a   Byington, R ^a   Chalmers, J ^a   Collins, R ^a   Dahlof, B ^a   Davis, B ^a   Estacio, R ^a   Fox, K ^a   Hansson, L ^a   Holman, R ^a   Hunsicker, L ^a   Kostis, J ^a   Kuramoto, K ^a   Kusek, J ^a   Lees, R ^a   Lewis, E ^a   Lindholm, L H ^a   Liu, L ^a   Lubsen, J ^a   Malacco, E ^a   Mancia, G ^a   Martin, I ^a   Pepine, C ^a   Pfeffer, M ^a   Pitt, B ^a   Poole Wilson, P ^a   Remuzzi, G ^a   Rodgers, A ^a   Ruggenenti, P ^a   Schrier, R ^a   Sever, P ^a   Sleight, P ^a   Staessen, J ^a   Teo, K ^a   Turner, R ^a   Wing, L ^a   Zanchetti, A ^a   Algert, C ^a   Woodward, M ^a   more..

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AMILORIDE; AMLODIPINE; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CAPTOPRIL; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; FELODIPINE; ISRADIPINE; LISINOPRIL; METOPROLOL; NICARDIPINE; NIFEDIPINE; NISOLDIPINE; NITRENDIPINE; PINDOLOL; QUINAPRIL; RAMIPRIL; TRICHLORMETHIAZIDE; VERAPAMIL;

ADULT; ANTIHYPERTENSIVE THERAPY; ARTICLE; BETA ADRENERGIC RECEPTOR BLOCKING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIURETIC THERAPY; FEMALE; HEART DEATH; HEART FAILURE; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; MORTALITY; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STROKE; TREATMENT OUTCOME;

AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CALCIUM CHANNEL BLOCKERS; CEREBROVASCULAR ACCIDENT; CORONARY DISEASE; FEMALE; HEART FAILURE, CONGESTIVE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS; TREATMENT OUTCOME;

EID: 0034627183     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(00)03307-9     Document Type: Article

References (46)

1. Blood pressure, stroke, and coronary heart disease. Part 2, short-term reductions in blood pressure: Overview of randomised drug trials in their epidemiological context
2. The effects of antihypertensive treatment on vascular disease: Reappraisal of the evidence in 1994
3. Blood pressure, antihypertensive drug treatment and the risks of stroke and of coronary heart disease
4. Effect of antihypertensive drug treatment on cardiovascular outcomes in women and men: A meta-analysis of individual patient data from randomised controlled trials
5. Health outcomes associated with antihypertensive therapies used as first-line agents: A systematic review and meta-analysis
6. Blood pressure, stroke, and coronary heart disease. Part 1, prolonged differences in blood pressure: Prospective observational studies corrected for the regression dilution bias
7. Cholesterol, diastolic blood pressure, and stroke: 13,000 Strokes in 450,000 people in 45 prospective cohorts
8. Blood pressure, cholesterol, and stroke in eastern Asia
9. MRC trial of treatment of mild hypertension: Principal results
10. Medical Research Council trial of treatment of hypertension in older adults: Principal results
11. Beta-blockers versus diuretics in hypertensive men: Main results from the HAPPHY trial
12. Cardiovascular risk and risk factors in a randomised trial of treatment based on the beta-blocker oxprenolol: The International Prospective Primary Prevention Study in Hypertension (IPPPSH)
13. Treatment of Mild Hypertension Study: Final results
14. Department of Veteran Affairs single drug therapy of hypertension: Final results
15. A 12-month comparison of ACE inhibitor and CA antagonist therapy in mild to moderate essential hypertension: The GLANT Study
16. Final outcome results of the Multicentre Isradipine Diuretic Atherosclerosis Study (MIDAS): A randomized controlled trial
17. Beta-blockade during and after myocardial infarction: An overview of the randomized trials
18. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure
19. Emerging role of angiotensin-converting enzyme inhibitors in cardiac and vascular protection
20. Effects of ACE inhibitors on mortality when started in the early phase of myocardial infarction: Evidence from the larger randomised controlled trials
21. Calcium channel blockers in acute myocardial infarction and unstable angina: An overview
22. Update of effects of calcium antagonists in myocardial infarction or angina in light of the Second Danish Verapamil Trial (DAVIT-II) and other recent studies
23. Effects of calcium antagonists on the risks of coronary heart disease, cancer and bleeding
24. Protocol for prospective collaborative overviews of major randomized trials of blood-pressure lowering treatments
25. Reliability of epidemiological evidence of treatment effects, I: Clinical trials
26. Long-term ACE inhibitor therapy in patients with heart failure or left-ventricular dysfunction: A systematic overview of data from individual patients
27. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin dependant diabetes and hypertension
28. Effect of angiotensin converting enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: The Captopril Prevention Project (CAPPP) randomised trial
29. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT)
30. Randomised double-blind comparison of a calcium antagonist and a diuretic in elderly hypertensives
31. Randomised trial of effects of calcium antagonists compared with diuretics and β-blockers on cardiovascular morbidity and mortality in hypertension: The Nordic Diltiazem (NORDIL) study
32. Randomised trial of old and new antihypertensive drags in elderly patients: Cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study
33. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39
34. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38
35. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients
36. Randomised, placebo-controlled trial of the angiotensin converting enzyme inhibitor, ramipril, in patients with coronary or other occlusive vascular disease
37. Effect of amlodipine on the progression of atherosclerosis and the occurence of clinical events
38. Angiotensin converting enzyme inhibition as antiatherosclerotic therapy: No answer yet
39. Long-term effects of cholesterol lowering and angiotensin-converting enzyme inhibition on coronary atherosclerosis: The Simvastatin/enalapril Coronary Atherosclerosis Trial (SCAT)
40. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension
41. Effects of intensive blood pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomised trial
42. Clinical results of the Verapamil in Hypertension and Atherosclerosis Study
43. The Verapamil in Hypertension and Atherosclerosis Study (VHAS): Results of long-term randomised treatment with either verapamil or chlorthalidone on intima-media thickness
44. Changes in hypertension treatment and in congestive heart failure mortality in the United States
45. Trials stopped early: Too good to be true?